Introduction
As high-throughput methods in experimental biotechnology reach technological maturity, genomic technologies such as gene expression array are expected to play a critical role in clinical translational research for complex disease diagnosis. However, there are stringent requirements in genomic medicine that have to be met. The ability to accurately and consistently discriminate disease phenotypes by determining gene expression patterns as signatures of different clinical conditions (e.g., three pathological stages of a tumor) is of particular importance. This has remained a challenge in translational bioinformatics due to the special characteristics of gene expression data. A gene expression dataset can be represented as a p × n matrix, where each column represents a gene (variable) and each row represents a sample (observation)
a . The number of variables (genes) is typically much greater than the number of observations, i.e. n p, even though only a small portion of the genes actually contribute biologically meaningful data variations for disease detection. Traditional pattern recognition methods, designed for low or medium dimensionalities of input data (smaller n that is more compatible with p), fail to achieve the requirements of clinical-level diagnosis.
Furthermore, gene expression data are notoriously noisy due to profiling variations, experimental design artifacts, and technical biases. In fact, normalization techniques are even ineffective in removing the 'systems noise' completely. They may also introduce false positives into the data 1 . Thus, translational bioinformatics methods for effective disease biomarker discovery and robust phenotype diagnosis from gene expression data must overcome the high dimensionality, information redundancy, and built-in noises, because they usually have caused traditional classification methods (e.g., discriminant analysis) to lose discriminative power.
The existing methods of biomarker discovery can be categorized into two groups, namely, gene-set methods and network methods. The gene-set methods identify a set of significant genes, i.e., gene markers from gene expression profiles using complicated biomarker capturing approaches (e.g., filter-wrapper methods) or feature selection methods to discriminate different disease phenotypes. Although widely employed, as a result of the gene expression data challenges mentioned above, the gene lists obtained from different gene expression studies can differ widely and share few common genes 2 . As such, there is no guarantee that good diagnosis achieved from one dataset can be generalized to another. In fact, the phenotype diagnostic performance from almost all gene-set methods lack stability and demonstrates strong dependence on input data. A method may work quite well for one dataset but fail badly on another. Alternatively, the network methods 2 don't view a biomarker as an individual genes. Instead, they view each biomarker as a small network, i.e., a subnetwork by incorporating protein-protein interaction (PPI) or even pathway information with the expression profiles. They employ subnetwork identification algorithms such as jActiveModule 3 , PNA 4 , and COSINE 5 to look for a set of subnetwork markers, which are usually orthogonal to each other, from expression data.
Although such a systems approach claimed in-depth insights into the underlying biological processes of complex diseases, they still have hard time to improve disease diagnostic accuracy not to mention to attain rivaling clinical phenotype discrimination. Especially, a noisy global protein-protein interaction (PPI) network may lead to subnetwork markers to include some unrelated "false positive" genes, which will decrease the discriminative power of the network markers and lead to poor diagnosis, because these methods usually search subnetwork markers from the global PPI network in a top-down fashion. Moreover, the subnetwork markers are usually orthogonal to each other and no information is available about gene regulators connecting them. However, those information can be essential to fully understand the dynamics of a disease from a systems viewpoint.
In this work, we develop a de novo feature selection method: Multi-ResolutionTest (MRT-test) to identify meaningful biomarkers from expression data. The MRTtest is based on our previous studies in local and global feature selection 6, 7 . We have found that our MRT-test is an exceptional way to extract subtle data characteristics in high dimensional omics data by capturing the local features of data in addition to removing system noise. Alternatively, as a novel disease biomarker discovery algorithm, our proposed MRT-test is particularly useful (as compared to existing methods) as it is able to identify meaningful biomarkers and demonstrate the linear separability of high-dimensional expression data.
We demonstrate that, by integrating our MRT-test with the state-of-the-art classifiers (e.g., SVM), we are able to achieve consistent clinical-level diagnosis accuracy across a series of gene expression data, whereas existing methods typically can only work well in one or two omics data. It is noted that we mainly use gene expression data in this study, though we also demonstrate our method's effectiveness in proteomics data. Furthermore, we propose a MRT-test based network marker discovery method: 'network marker synthesis' (NMS ) to seek network markers by 'growing' the 'seed' gene markers from the MRT-test. As a bottom-up network approach, it has less dependence on the global network for its more targeted search and enables the identification of gene regulators for the subnetwork markers to reveal underlying tumorigenesis, in addition to demonstrate rivaling clinical phenotype diagnosis, because of its more targeted search initialized by our MRT-test identified gene markers.
Methods
We provide some background on feature selection in section 2.1 before we introduce our Multi-Resolution-Test (MRT-test) method in section 2.2.
Background on feature selection
The proposed MRT-test extends our previous work in local and global feature selection to input-space feature selection 6, 7 . We first categorize feature selection as either subspace or input-space feature selection before introducing the MRT-test. The former seeks to find meaningful feature combinations in a low dimensional subspace induced by a linear or nonlinear transform (e.g., PCA). The latter selects a feature subset in the same space as input data through conducting a statistical test (e.g., t-test) or building different feature filtering models according to different selection criteria (e.g., filter-wrapper methods). Due to the high dimensionality of gene expression data, input-space feature selection methods are often used for its efficiency and simplicity. The two-sample t-test and its variants are probably the most popular input-space methods in gene expression analysis. However, similar to other input-space approaches, they have the following limitations.
First, these methods usually assume input data 'clean' or 'nearly clean' and ignore necessary de-noising in feature selection. Such an assumption may not be appropriate because the noises in gene expression data can be non-linear. This means that they are more than white noises or non-differential ones, and they can cause statistical tests (e.g., the t-test and even its more sophisticated extensions) to lose robustness. For example, the noises would behave as 'outliers' by participating in t-score calculations for each gene, and cause the sample means from the two groups of a gene (e.g., cancer vs. control) to be very close, which usually results in a zero or an approximately zero t-score. As such, the t-test's robustness may be significantly decreased, leading to biased feature selection, i.e., "pseudo-significant" genes are selected while "truly-important" genes are filtered. This may inevitably limit the subsequent classifier's phenotype discrimination, generalization, and stability.
Second, these methods are single resolution approaches, where all features are indistinguishably displayed in one resolution despite the nature of their frequencies. As such, the high frequency features will have a high likelihood to be picked up in feature selection than those low frequency ones. The high (low) frequency features refer to those features which appears the more (less) often in the input space respectively. Furthermore, we refer to the high frequency and low frequency features in the input space as global features and local features, which describe global/local data characteristics and capture general/subtle data behaviors, respectively. The local features can be viewed as signals occurring at a short time interval (e.g., transient signals with sharp peaks), while the global features can be viewed as signals observed often in a long time interval.
For example, a gene whose expression plot curve is similar to those of most other genes is a global feature. On the other hand, a gene with several exceptional local "high peaks" on control, which are rarely found on most other genes, would be a local feature. The local features are key to discriminating samples sharing similar global characteristics but with different local characteristics to achieve high diagnosis accuracy in translational bioinformatics. For example, Different subtypes of tumors may share similar global characteristics but different local characteristics in their expression data according to their different pathological states.
However, the local features are hard to extract by traditional feature selection methods, where each feature is an indecomposable information unit, because the global features may always have a high likelihood to be selected for their highfrequency. As a result, there are redundant global characteristics involved in disease phenotype discrimination because global feature dominated data will enter the subsequent classifier (e.g., SVM) used for diagnosis. However, the redundant global features may overshadow the subsequent classifier's training phrase and lead to a decision rule only favoring those global features. As such, the resulting classifier would fail to diagnose the samples with similar global characteristics but different local characteristics.
To some degree, the redundant global features act as 'external noise' along with the built-in noise to affect the classifier's discrimination and generalization capabilities, and increase the risk of mis-diagnosis and over-fitting. For this reason, such classifiers may demonstrate large oscillations in performance for different data, i.e., it may fit some data well but poorly on others, due to the global features' unpredictable contributions to phenotype discrimination. In this study, we present a novel feature selection model: Multi-Resolution-Test (MRT-test) designed to extract local features, conduct de-noising, and avoid redundant global features so as to enhance biomarker discovery by detecting subtle changes in expression of the few genes causing disease, and achieve rivaling clinical phenotype diagnosis.
Unlike traditional feature selection methods, the MRT-test makes local feature extraction and de-nosing possible by incorporating a screening mechanism to separate the global and local features via discrete wavelet transform (DWT) 8 based multiresolution analysis. It is noted that we view each entry of a gene in the DWT as a sampling point at a specific time point, and the entries belonging to different types (e.g., cancer type) are points sampled at different time intervals.
For example, given a gene from an omics data set with 40 cancer and 50 control samples, we view the 40 entries from the cancer type and 50 entries from the control type as the sampling points from time intervals 1 and 2 respectively. The reason for this assumption is that we implicitly view gene expression data as a kind of special time series data, where different types of observations are samples from different biological time intervals. For example, three pathological stages of a certain tumor correspond to three different biological time intervals.
The MRT-test can be sketched as following steps. At first, a discrete wavelet transform (DWT) with a transform level L is applied to input data X column-wise to decompose it hierarchically as L detail coefficient matrices:
and an approximation matrix A L . It is noted that we assume input expression data X have n columns of genes and p rows of samples in our context. Since DWT is done on a set of dyadic grid points hierarchically, the dimensionalities of the approximation and detail coefficient matrices shrink dyadically level by level. For example, given input data with 100 samples across 1024 genes under the DWT with a transform level L = 4, D 1 is a 100×512 matrix and D 2 is 100×256 matrix. Similarly, D 4 and A 4 both are 100×64 matrices. That is, given input expression data with p samples and n genes X = [x 1 , x 2 , . . . x n ],x j ∈ p , a L-level DWT is applied to such data set gene by gene to obtain L number of detailed coefficient ma-
e., such a transform can be summarized as
The approximation matrix and coarse level detail coefficient matrices (e.g.,
capture the global data characteristics, because they contain contributions from the features disclose data behaviors usually often observed in 'long-time windows'. Similarly, the fine-level detail coefficient matrices (e.g., D 1 , D 2 ), capture the subtle (latent) data characteristics, because they contain contributions from those features describing less-often data behaviors observed in 'short-time windows'. In fact, these fine-level detail matrices are components to reflect data derivatives in different time windows. Furthermore, most system noise is hidden in these components for its heterogeneity with respect to the 'true' signals. In summary, the first step separates the global characteristics, subtle data characteristics, and noise in different resolutions.
Second, we retrieve the most important subtle data behaviors and remove noise by reconstructing the fine-level detail coefficient matrices before or at a presetting cutoff level τ (e.g., τ=3). Such construction consist of two steps: 1) We apply principal component analysis (PCA) to each of the detail coefficient matrices D 1 , D 2 · · · D τ to obtain its principal component (PC) matrix U and score matrix S.
2) We employ the first loading vector (1 st PC), the 1 st column in the PC matrix U, to reconstruct each coefficient matrix D j , j = 1, 2, · · · τ, to retrieve the most important subtle data behaviors described by this fine-level detail coefficient matrix. We have to point it out that such the first principal component based reconstruction is actually a de-nosing process also. This is because only the maximum variance direction (the 1 st PC direction) is employed in reconstructing each targeted fine-level coefficient matrix and those less important and noise-contained principal components are dropped in reconstruction.
In fact, we have found that the first PC direction counts quite a large percentage of data variance (e.g., 60%) for each fine-level detail coefficient matrix in a gene/protein expression array data. Moreover, as we pointed out before, the system noise is usually transformed to those fine-level detail coefficient matrices (e.g., D 1 ) for its heterogeneity by the DWT. Thus, using the 1 st PC in the fine-level coefficient matrix reconstruction would guarantee the maximum de-noising and the most significant subtle data behavior retrieval.
Alternatively, the coarse level detail coefficient matrices after the cutoff τ :
approximation coefficient matrix A L are kept intact to retrieve these global data characteristics. Since the local data characteristics extraction and system noise removal are achieved through decomposing features in the multi-resolution data approach, we avoid the global feature dominance problem faced by the traditional feature selection methods, which would contribute to the following phenotype diagnosis. It is worth pointing out that, although theoretically feasible, using several leading loading vectors instead of the 1 st PC in the detail coefficient matrix reconstruction may not achieve desirable de-noising, especially under a 'large' τ value (e.g., τ = 16).
Third, a corresponding inverse DWT is applied to the current coefficient matrices and the approximation matrix to calculate a meta-profile X * , which is a same dimensional synthesis of the original data but catch subtle data characteristics and has less memory storage because less important principal components are dropped in our detail coefficient matrix reconstruction. Moreover, the meta-feature of each feature (e.g., gene), i.e., the expression values of the feature in X * , has values in a relatively smaller range than that of the original feature due to the leading PC based detail coefficient matrix reconstruction. For the same reason, the data variances of the meta-profile X * are smaller than those of the original omics data X. Finally, we employ t-statistic and F-statistic to score each feature, i.e., gene, for the binary class and multi-class cases respectively. The genes with the most statistically significant scores will be chosen as gene markers. It is noteworthy that de-noising and local feature extraction process in steps 2 and 3 make the phenotype distributions in the meta-profile X * fit better into the normal distribution than those of the original data X, which theoretically contributes to the effectiveness of the MRT-test. The detailed MRT-test algorithm is presented as follows.
(1) Wavelet multi-resolution analysis. Given an expression dataset with p observations and n variables X = [x 1 , x 2 , . . . 
, and cor-
. ii. Reconstruct each matrix D j by using the first loading vector u 1 in the PC matrix as
, with all entries being '1's.
(3) Meta-profile synthesis. Conduct the corresponding inverse DWT using the updated coefficient matrices
p×n , which is a same-dimensional de-noised data with local feature extracted. (4) Meta-profile hypothesis testing.
(a) For a binary class input data, calculate a t-statistic (t = |x − y|/ s 2 x /n x + s 2 y /n y ) for each gene/feature in the meta-profile X * , wherē
x andȳ are the sample means, s 
,where n j is the sample size, parameters, and x * j and s 2 j are the sample mean and sample variance for the j-th class. x * = k j=1 nj i=1 x * ij /n T is the overall sample mean where x * ij is the expression value of i-th observation for the class j and n T = T j=1 n j is the total sample size for the k groups. (c) Select a feature set S that includes statistically significant genes by picking genes with the smallest p-values (or the largest testing statistic) from tdistribution or F -distribution with a pre-specified significant value α (e.g., α = 0.05 ). These genes in S are different from the original ones because they went through de-noising and local feature extraction.
We uniformly conduct a 12-level DWT with a 'db8 ' wavelet for input data by setting the level threshold τ = 4 in the MRT-test due to its good performance. It is noted that we require the wavelet ψ employed in the DWT to be orthogonal and have a compact support such as Daubechies wavelets for the sake of subtle data behavior capturing. In fact, we suggest an empirical threshold: 3 ≤ τ ≤ L/2 . A threshold (say, τ = 1) that is too low may affect the quality of de-noising as some noise may still enter the meta-profile through a fine coefficient matrix (e.g., D 2 ) without reconstruction, which can cause our method to fail to extract some local features. On the other hand, using a threshold (say, τ > L/2 ) that is too high may miss some global features for the first load vector based coefficient reconstruction. In this paper, we choose the wavelet 'db8 ' as it is not only orthogonal but also smooth for capturing subtle data behavior in DWT.
Results
We have performed comprehensive experiments to evaluate our proposed MRT-test based techniques for four different tasks, namely, biomarker discovery (Section 3.2), phenotype diagnosis for binary and multiclass data (Section 3.3), comparison with the state-of-the-art diagnostic methods (Section 3.4), as well as a MRT-test induced network marker identification (Section 3.4), in addition to applying the MRT-test to proteomics data (section 3.5).
Data sets
We employ six binary and two multiclass benchmark gene expression array data in our experiment. We say these data are 'heterogeneous' because they were produced from different profiling technologies, experiments, and processed by different normalization methods. We summarize the data sets in a little detailed way.
Stroma data consist of 47 samples from two subtypes of breast cancers: 13 inflammatory breast cancers ('ibc') and 34 non-inflammatory breast cancers ('nonibc' ) across 18995 selected genes 9 . Inflammatory breast cancer is a relatively rare but very aggressive disease that cancer cells block lymph vessels in the skin of breast. Compared with other types of breast cancer, it progresses rather rapidly and is very hard to diagnosis, though a PET or CT scan may help diagnosis. It has a low prognosis ratio (e.g., 34% 5-year relative survival). A molecular diagnosis via gene expression array is essential to early discovery of such cancer and its prognosis.
Colon data may be one of earliest benchmark data in translational bioinformatics that consist of 22 control and 40 cancer samples across 2000 selected genes 10 . Since it is a data published in early years (1999), we can view the oligonucleotide array technology used by this data set is different from current oligonucleotide array technologies. However, it can be a good candidate to validate the effectiveness of our MRT-test algorithm across different types of data.
Medulloblastoma data consist of 25 classic and 9 desmoplastic tumor samples across 5893 genes that represent two subtypes of medulloblastomas, an early childhood carcinoma whose pathogenesis is not well understood yet 11 . Similar to the Colon data, both Prostate 12 and Breast 13 data are widely used benchmark data but generated by early oligonucleotide array technologies. The former consists of 59 normal controls and 77 prostate cancers across 12625 selected genes, and the latter consists of 46 tumor samples with metastasis in 5 years and another 51 tumor samples without metastasis in 5 years across 24188 probes. It is noted that the Breast data set is also well-known for its low diagnosis ratio (classification accuracy) for different classifiers 2, 7 . Different from the previous carcinoma expression data, Smoke data consist of the gene expression of 34 current smoking subjects and 23 never-smoking subjects by high-density gene expression arrays 14 . Alternatively, as its three-class extension, SMOKE data includes the 18 former smokers in addition to 34 current smokers and 23 non-smokers 14 . Although such data demonstrated how smoking altered the transcriptome, and why former smokers had risk to develop lung cancer even long after they quitted smoking, it was important but still unexplored yet to distinguish current smokers, former smokers and non-smokers from their expression data from a translational bioinformatics approach.
As a widely used tumor data, CNS ( central nervous system) data set consists of 10 medulloblastomas ('Md '), 10 malignant gliomas ('Mg'), 10 rhabdoids ('Rhab'), 4 normal human cerebells ('Ncer '), and 8 supratentorial PNETs ('PNET ') across 5669 selected genes 15 . Although previous work showed medulloblastomas were molecularly distinct with the other brain tumors 15 , it is quite challenging to separate all the five brain tumors with each other completely. Tables 1 sketch information about these 'heterogeneous' expression data. In addition to these eight major omics data sets, we also include a gene expression array data: wang-breast, which consist of 163 breast cancer patients with ER≥10 fmol per mg protein and 53 breast cancer patients with ER < 10 fmol per mg protein across 2000 selected genes in this study 16 . As a local feature selection algorithm with a de-noising scheme, the MRT-test is also a biomarker discovery algorithm that is effective in discovering specific genes as biomarkers that are able to disclose subtle data behaviors in addition to general data behaviors. We systemically demonstrate effective biomarker identification by the MRT-test for binary-class and multiclass data. Unlike other biomarker discovery methods, the proposed MRT-test can completely separate phenotypes of high-dimensional array with few top-ranked genes. In contrast with general assumption that high-dimensional gene expression arrays are non-separable nonlinear data, Our results strongly demonstrate they are actually linearly separable data through concrete examples.
Biomarker discovery for binary-class data
We firstly compare 3 top-ranked genes (biomarkers) from the MRT-test with those from the t-test as well as 3 randomly picked genes for Stroma data set, a binary-class array data with 13 'ibc' and 34 'non-ibc' samples. Figure 1 separates Stroma data's 47 samples with 3 randomly selected genes, the top 3 ranked genes from t-test and from MRT-test. We choose two different cutoff values τ = 3, 4 for the MRT-test in our experiment to fully explore its biomarker discovery mechanism. Each blue (yellow) dot in Figure 1 represents an 'ibc' ('non-ibc') sample. The x, y, and z axes represent expression values of the 1 st , 2 nd , and 3 rd gene marker respectively. The top 3 genes from the t-test showed some degree of phenotypic separation than those randomly selected ones, which indicates the t-test demonstrating some degree phenotype discrimination ability. However, it is still unable to separate the two types of phenotype samples clearly. This implies that while the t-test can be used for feature selection, it is ineffective as a biomarker discovery algorithm for separating phenotypes.
In contrast, the two sets of top-ranked three genes from the MRT-test both demonstrated clear spatial separations for the 13 'ibc' and 34 'non-ibc' samples. It is noted that the samples sharing the same phenotype are clustered automatically in an independent group with a well-built spatial boundary that separates the two different phenotypes.
On closer investigation, three sub-clusters can be further identified for the 'nonibc' samples, which may indicate different pathological stages of 'non-ibc' breast cancer. Such 'self-clustering' of the samples from the different phenotypic classes (or even subclasses) strongly suggests that the MRT-test is a much more effective biomarker discovery algorithm that can detect discriminative gene markers.
It is worth noting that the top-ranked gene markers detected by our MRT-test also demonstrated significant biological relevance with breast cancer. 'GOLGB1 ', the top-ranked gene both with τ = 3 and 4, has been reported as a gene that is strongly correlated to the inflammatory carcinoma of breast 917 . It also interacts with gene 'BRMS1 ', a breast cancer metastasis suppressor, and gene 'ACBD3' that plays an important role in asymmetric cell division and breast cancer 18 . The second and third top-ranked gene markers from our MRT-test (τ = 3) are 'CCNT2 ' and 'CBY1 ', both of which were also reported to have tissue expression in breast tumors. In addition, the 'CCNT2 ' gene regulates 'CDK9 ', which was reported to be closely related to the breast cancer in Johnston et al 's work 19 . 'CBY1 ', the 3rd top-ranked gene, can inhibit wingless pathway by binding to beta-catenin, which is a transcriptional activator and oncoprotein involved in the development of breast tumor and other cancers 20 . In addition to sharing the first top-ranked gene, the third top-ranked gene 'CBY ' from the MRT-test at τ=4 is also the third top-ranked gene at τ = 3, which suggests the reproducibility of our MRT-test. The second top-ranked from the MRT-test at τ = 4 is 'TOX3'. As a previously identified biomarker for breast cancers, Easton et al. suggested that mutations from the 'TOX3 ' gene are associated with an increased risk of breast cancers 21 . It is noted that we also compared our MRT-test with other feature selection methods such as permutation t-test (pt-test), Bayesian t-test (bt-test), and MannWhitney tests (u-test) by finding the three top-ranked genes according to their p-values. We have found all these methods have achieved almost same level performance as the t-test. That is, they are unable to achieve a perfect phenotype separation like the MRT-test, though they demonstrate better phenotype separation than the random gene selection. Such a result suggests these methods are just general feature selection methods instead of a biomarker discovery algorithm like our MRT-test. Furthermore, we have to point out that the reason we use the three top ranked genes for biomarker discovery is just to demonstrate the gene markers identified by our MRT-test can separate the phenotype linearly from a 3D visualization viewpoint. In fact, more top ranked genes (e.g., top 20 scored genes) can be invited in biomarker discovery.
3.2.2.
Compare top-ten ranked genes from the MRT-test and t-test. smaller than those of in the t-test, which statistically indicates the better sensitivity of our MRT-test, which will be further validated in the next section. In addition to the top three genes, other genes identified by the MRT-test were reported to be related to breast cancer. For example, EIF4A2 was inversely expressed in breast cancer 22 ; TBL1X was reported over-expressed in breast cancer 23 ; DIDO1 (Death inducer-obliterator) was related to expression level control of breast cancer 24 ; ABAT and SPI1 were associated with the prognosis of breast cancer 25 . However, there are 5 genes among the total 9 genes (one is duplicate) in the t-test's gene list are not reported to be related to breast cancer in current available literature such as USP46, ARFRP1, TTC3, DKFZP686A01247, and DZIP3, which may suggest the ad-hoc of the t-test. The top-10 genes ranked by the MRT-test at τ = 4 can be found in Table S1 in the supplemental materials, which can be found at https://sites.google.com/site/heyaumsystembiology/.
3.2.3.
MRT-test for Colon, Breast, Medulloblastoma, and Wang-breast data.
Gene expression array technologies have seen great progresses in recent years, which may contribute to enhancing biomarker's capability in phenotype separation. However, the biomarkers identified by our MRT-test (τ = 4) demonstrate exceptional phenotype separation capability for different array data produced by different time and experiments. Figure 2 demonstrates phenotype separation by using the three gene markers identified by the MRT-test for four data sets: Colon, Breast, Medulloblastoma, and Wang-breast data, published in 1999, 2002, 2003, and 2005 respectively 10, 13, 11, 16 . It is noted that the Colon data has been widely used in secondary data analysis. However, there was no method able to separate 22 controls and 40 cancers completely. Our MRT-test firstly achieved this by only using three gene markers, which may indicate that our MRT-test is independent of data sets. It not only works for the Stroma data, which is a relatively new array data published in 2008, but also old array data like the Colon data.
Although the Breast data set that consisting of 46 'metastasis' and 51 'without metastasis' samples is well-known for its poor diagnostic accuracy from previous studies 2 , all 97 samples are well separated spatially by our method: there were no mixed samples and the resulting two distinct groups are clearly separated by an easily identified boundary (NW plot in Figure 2 ). This indicates that this previously thought of a 'hard ' high-dimensional data set is actually linearly separable using our biomarkers detected by the MRT-test. The similar linearly separable scenario is demonstrated for the Wang-breast data with 216 breast cancer samples by the SE plot in Figure 2 .
Furthermore, the SW plot in Figure 2 shows the complete separation of 25 classic and 9 desmoplastic samples in the Medulloblastoma data by three MRT-test identified gene markers, where two obvious clusters can be easily identified. To our best knowledge, there were no clustering or biomarker discovery methods able to group the 25 classic and 9 desmoplastic samples into two well-formed independent clusters. This again illustrates that the MRT-test is able to accurately detect novel biomarkers which are difficult to be identified by existing methods.
In fact, previous studies showed that a distinct desmoplastic class could not be discovered by using traditional clustering methods such as hierarchical clustering or self-organizing maps 11 . In other words, there was no way to group all 9 desmoplastic samples into a cluster which is also an "evidence" to support that such data are nonlinear data with the least hope to achieve rival clinical diagnosis. Brunet et al employed a quite complicate nonnegative matrix factorization (NMF) based consensus clustering, which is a high-complexity algorithm, and only grouped seven desmoplastic samples into a cluster, where two desmoplastic samples were still scattered into the group of the classic samples 11 .
Biomarker discovery for multiclass array data
Our MRT-test also demonstrates a similar phenotype separation for multiclass array data SMOKE and CNS. It is noted that relatively few multiclass biomarker discovery algorithms are available for multi-class data due to the complexity of multiclass classification itself and corresponding low detection ratios. However, multiclass array data are quite common due to several subtypes of a tumor or different pathological states of a disease. Since gene expression data usually follow or approximately follow a normal distribution after normalization, it is reasonable to use a one-way ANOVA to identify the most significant genes as potential biomarkers for a multiclass data set. Thus, we compare our MRT-test with one-way ANOVA, which can be viewed as an extension of the t-test in multiclass scenarios, for multiclass expression data biomarker discovery. Figure 3 employs the 3 top-ranked genes from ANOVA (one-way ANOVA) and the MRT-test (τ=4) to separate SMOKE data that consists of 18 previous smokers ('smoked '), 34 current smokers ('smoking'), and 23 non-smokers ('non-smoking') 14 , as well as the CNS data that consists of 10 medulloblastomas ('md '), 10 malignant gliomas ('mg'), 10 rhabdoids ('Rhab'), 4 normal human cere-bells ('Ncer '), and 8 supratentorial PNETS ('PNET ') across 5669 genes 15 . The NW plot in Figure 3 shows there are no obvious separations for samples from different phenotypes for the SMOKE data under ANOVA. However, the NE plot in Figure 3 demonstrates that three independent clusters: 'smoked', 'smoking', and 'non-smoking', can be easily identified from our MRT-test. It is interesting to see that the 'smoked' cluster seems to have much closer distance to the 'smoking' cluster than the 'non-smoking' cluster, which seems to be consistent to the previous results that former smokers had risk to develop lung cancer as current smokers 14 . Similarly, the SW plot in Figure 3 shows that only four 'Ncer ' samples were separated from the other 38 CNS samples using gene markers from the ANOVA. However, once again, the SE plot in Figure 3 demonstrates clear phenotypic separations were achieved by using the gene markers: 'APC', DCTN1', 'APBA2' from our MRT-test in these multiclass scenarios.
The three selected gene markers are well-known oncogenes related to medulloblastoma, glioma, and neuron diseases, where 'APC' and 'APBA2' mutations were reported to play an important role in medulloblastoma 26 ; DCTN1 was reported associated with neuron diseases and glioma respectively 27 . It is also interesting to see that these medulloblastoma samples are spatially much closer to the those malignant glioma samples than others (See SE plot in Figure 3) . Actually, these two diseases have very similar or same symptoms such that medulloblastoma was confused as glioma for years before their different pathologies were found in 28 . It is worth pointing out that our phenotypic separation on the CNS data is superior to that by Pomeroy et al's approach 15 , which employed PCA analysis for the 50 genes ranked by SNR (signal-to-noise) ratios. However, compared with our complete separation of five classes by using only three gene markers, Pomeroy et al's approach has one 'Mg' out of its group and makes eight 'PET ' samples spread too much such that they can be somewhat mixed with 'Md' and 'Mg' samples. In summary, the experimental results across six data sets clearly demonstrate that our MRT-test is a powerful biomarker discovery algorithm that is able to demonstrate linear separability in gene expression array data that other methods have failed to do so.
MRT-test phenotype diagnosis
It is desirable to validate these biomarkers identified by the MRT-test from a diagnostic viewpoint under data cross-validation and further explore the MRT-test's discriminative power for a number of genes identified by the MRT-test. Thus, we ex-amine the MRT-test phenotype diagnosis by combining it with the state-of-the-art classifiers such as support vector machines (SVM) and linear discriminant analysis (LDA), in addition to comparing the MRT-test with different variants of the t-test and one-way ANOVA. We skip the detail descriptions about SVM and LDA. More detailed information about these two classifiers can be found in 7,29 .
Binary phenotype diagnosis.
We employ a support vector machine (SVM) with a 'linear ' kernel under standard 5-fold cross-validation (5-fold CV) to evaluate several sets of top-ranked genes from the MRT-test for binary class data. It is noted that each gene set identified by the MRT-test are de-noised and local feature extracted. Figure 4 shows the SVM's diagnostic performance in terms of accuracies (diagnostic ratios), sensitivities, specificities, and positive prediction rates for six binary data sets using the 3, 10, 50, 100, 200, 500, and 1000 top-ranked genes from the MRT-test. Each data set in Figure 4 is represented by its first letter, where 'S' and 'S1' represent the Stroma and Smok e data respectively. The reason for us to select a relatively large gene set (e.g., a set with 100, 200, or even 500 top-ranked genes) for phenotype diagnosis is that we plan to demonstrate the proposed MRT-test is not only a good biomarker discovery algorithm but also an exceptional feature selection algorithm, which will bring rivaling clinical performances for high dimensional omics data. We briefly sketch these diagnostic performance measures for the convenience of description as follows. The diagnostic accuracy is the ratio of the correctly classified test samples over total test samples. The sensitivity, specificity, and positive predication ratio are defined as the ratios: TP/(TP+FN), TN/(TN+FP), and TP/(FP+TP) respectively. The TP(TN) is the number of positive (negative) targets correctly diagnosed, and FP (FN) is the number of negative (positive) targets incorrectly diagnosed by the classifier (e.g., SVM). A positive (negative) target is a sample with '+1' ('-1') label, which usually represents 'cancer' ('control') or a subtype of tumors respectively. Figure 4 shows that clinical level prediction ratios with only a few genes are consistently achieved for most data sets. For example, the three top-ranked gene markers for the Smoke, Colon, Medulloblastoma, and Breast data achieve 100%, 96.93%, 96.68%, and 99% diagnostic accuracies respectively under the 5-fold CV. Although the three top-ranked gene markers for the Stroma data only achieve˜92% diagnostic accuracy, it is probably because the relatively too close distance between two boundary samples, i.e. support vectors, and corresponding numerical artifacts in the optimal SVM hyper-plane construction cause the classifier not to be able to determine a specific sample's class type. This can be used to explain why the diagnostic accuracies of some data are not perfect 100%, even if their three selected gene markers can separate two different phenotypes spatially. However, the SVM classifier attains 100% accuracy on the Stroma data by using the 10 top-ranked genes. The same level performance remains for the 50,100, and 200 top-ranked gene scenarios.
Interestingly, the SVM classifier demonstrates an 'early-arrival ' in phenotype diagnosis for almost all data, i.e., only a few genes are needed to achieve nearly perfect sensitivity and specificity. It suggests that using more genes as biomarkers may not necessarily enhance diagnostic performance, because more less-discriminative genes may be included in training data that leads to lower the classifier 's performance. For example, the SVM attained slightly low 97.78% accuracy (sensitivity: 100%, specificity: 90%) for the 500 and 1000 top-ranked genes. However, such 'earlyarrival' in diagnosis is consistent with the biomarker separation results presented in the previous section.
Although our SVM did not achieve as a 'good' performance on the Prostate data under the 3, 10, and 50 top-ranked genes, it still achieved a 97.78% (sensitivity: 98.65%, specificity: 96.52%) accuracy for the 100 top-ranked genes and 100% for the 200 or more genes, which indicates that more biomarkers are needed to distinguish different phenotypes for this dataset. It can be viewed as a special case of the 'early arrival' mechanism. Although we did not include Wang-breast data in our experiment for it is not the original data but a data set already going through a previous feature selection, it is worthwhile to report that the SVM classifier can reach 98.60% (sensitivity: 98.77%, specificity:98.00), 99.07% (sensitivity: 98.77%, specificity:100.00%), and 99.53% (sensitivity: 99.38%, specificity: 100%) accuracies under the 3, 10, and 50 top-ranked genes from our MRT-test. However, the SVM classifier can only achieve˜85% accuracy for this data set under the same cross validation without feature selection.
Compare the MRT-test with the other feature selection methods.
Just as we pointed out that our MRT-test is a novel feature selection algorithm besides a biomarker discovery method. It is necessary to compare the MRT-test with other similar feature selection methods to further demonstrate its superiority. We select five input-space feature selection methods as the comparison peers, which include t-test, Bayesian t-test ('bt-test') 34 , and permuted t-test ('pt-test') 35 , ROC curve area ('roc') 36 , and Mann-Whitney tests ('u-test') 37 . We employ the MRT-test and the five peers to select two gene sets: one with with 100 top-ranked genes, another with 200 top-ranked genes for each data. Then, we run the SVM classifier with a linear kernel for all these data sets under 5-fold cross validation to compare their diagnostic accuracies. Figure 5 shows the SVM classifier 's diagnostic accuracies for the two gene sets selected by six feature selection methods respectively under the 5-fold CV for six binary data sets. It is clear that the SVM classifier demonstrates consistently leading performance for all gene sets from the MRT-test than those from the others. Interestingly, the SVM classifier shows relatively low accuracies and high-level oscillations for the gene sets from the five comparison peers, which seems to indicate the unpredictable impacts of these methods on diagnosis.
For example, the SVM classifier achieves 98.46% diagnostic accuracy for the Colon data for the gene set with 100 top-ranked genes from the MRT-test. But it only attains 82.82%, 87.56%, 72.56%, 79.23%, and 79.74% for the same-size gene sets from t-test, bt-test, roc, and pt-test respectively. Furthermore, the same classifier only attains 85.64% diagnostic accuracy on the 200 top-ranked genes from the bttest, which is lower than the 87.56% accuracy obtained on the 100 top-ranked genes. In fact, relatively low and oscillated accuracies are observed for those genes from the other methods on different data sets. It is also worthwhile to point out that similar scenarios are observed even when more genes are selected (e.g., 500 and 1000 genes).
It is clear that the MRT-test is corresponding to the rival clinical diagnosis on these binary data, where Bayesian t-test ('bt-test' ) and t-test are corresponding second-level diagnosis, the roc and u-test are corresponding to the third-level diagnosis, and the permutation t-test (pt-test) seems to have the worst performance from a diagnostic viewpoint. The results suggest that the MRT-test's capability in selecting unique and discriminative local features enhances robust and accurate binary phenotype diagnosis. 
Multiclass phenotype diagnosis
Multiclass phenotype diagnosis has been a challenging problem in translational bioinformatics for its usually low accuracies due to the complexity of multiclass data classification itself. We employ the two multiclass data sets: SMOKE (threeclass) and CNS (five-class) data in our experiment to demonstrate the MRT-test's superiority in multiclass phenotype diagnosis.
We use 'one-against-one' SVM to handle multiclass phenotype diagnosis because its proven advantage over 'one-against-all ' and 'directed acyclic' SVM 30 , in addition to taking advantage of linear discriminant analysis (LDA)'s build-in multiclass handle mechanism. Moreover, we combine the MRT-test with the 'one-against-one' SVM and LDA to get corresponding MRT-SVM and MRT-LDA algorithms, where input data consist of the top-ranked genes from the MRT-test. Similarly, we integrate one-way ANOVA with the two classifiers to get corresponding ANOVA-SVM and ANOVA-LDA algorithms, where input data consist of top-ranked genes from the one-way ANOVA. They act as the comparison algorithms for our MRT-SVM and MRT-LDA in multiclass phenotype diagnosis. To be consistent with the previous section, we still employ the same 'linear' kernel for the 'one-against-one' SVM and conduct 5-fold cross validation for each data. Figure 6 compares the performance of the MRT-SVM and MRT-LDA with the ANOVA-SVM and ANOVA-LDA classifiers in terms of diagnostic accuracy, sensitivity, and specificity for a sequence of 3, 10, 50, 100, 200, 500, 1000 and 2000 top-ranked genes from the ANOVA and MRT-test respectively for the SMOKE and CNS data. It is interesting to see that the 'early-arrival ' phenomenon can still be obervsed for the MRT-SVM and MRT-LDA classifiers in addition to their rival clinical diagnosis, For example, the MRT-LDA achieved 93.06% accuracy with the 3 top-ranked genes from the MRT-test on the CNS data, whereas ANOVA-LDA only manages a low 64.72% accuracy with the 3 top-ranked genes from the ANOVA.
Similarly, the MRT-SVM achieved 98.75% accuracy on the SMOKE data with only 10 MRT-test selected genes, which seems to be consistent with the previous biomarker discovery results, whereas the ANOVA-SVM only achieved a low 63.83% accuracy with the 10 ANOVA selected genes. The results show that the MRT-test is also more effective in choosing distinguishing biomarkers for multiclass phenotype diagnosis. Furthermore, we observe that the MRT-test well demonstrates the advantages of effective feature-selection in multiclass phenotype classification, since the original 'one-against-one' SVM and LDA algorithms without any feature selection can only achieve 63.83% and 54.67% on the SMOKE data, and 90.56% and 88.06% accuracies on the CNS data respectively. 
Comparison with other state-of-the-art algorithms
We further compared our MRT-test based methods: MRT-SVM and MRT-LDA with six other state-of-the-art classifiers for total eight gene expression array data, where the MRT-SVM employs the standard SVM and 'one-against-one' SVM for each binary and multiclass data respectively.
The six comparison classifiers consist of two PCA-induced classifiers: PCAinduced linear discriminant analysis (PCA-LDA) and PCA-induced support vector machines (PCA-SVM) 6 , two partial least square (PLS) based regression methods: PLS-based linear logistic regression (PLS-LLD) 31 , a PLS-based ridge penalized logistic regression (RPLS ) 32 , and an ensemble learning method: a decision tree with bootstrap aggregation (DS-TREE ) 33 . It is worthwhile to point out that, like PCA, PLS is also a subspace feature selection algorithms that seek the meaningful feature combinations in a low dimensional space. Due to different 'early-arrivals' of the MRT-SVM and MRT-LDA for different data sets, we compared the performance for the top-ten ranked genes for all the seven datasets and the top-100 ranked genes for the Prostate data. Figure 7 compares the performance of the MRT-test based methods with the other methods in terms of diagnostic accuracies under the 5-fold CV. It indicated that our MRT-test based methods outperformed the others in terms of accuracies and stability. For example, MRT-SVM and MRT-LDA achieved both 100% accuracies for the binary smoke data, and 97.50% and 98.75% accuracies for the three-class SMOKE data respectively, whereas the best performance from the other peers are only 91.67% and 82.70%. It seems that the MRT-SVM achieved the best diagnostic performance on all data, and the MRT-LDA algorithm achieved second-best performance on all seven datasets except Prostate data, on which it appeared to encounter down-fitting. Moreover, the SVM, PCA-SVM and PCA-LDA classifiers appeared to achieve same level diagnostics that may suggest PCA may not contribute to enhancement of diagnostics statistically for SVM. It also seems that the PLS-LLD algorithm outperformances all the other five classifiers except the MRT-SVM and MRT-LDA for the eight data sets, in addition that the decision tree method has the worst performance.
Unlike the other methods demonstrating large oscillations in performance, our MRT-test based methods again demonstrated consistency in attaining high-level phenotype discrimination in 'hetergeneous' binary and multi-class expression data. This suggests that our proposed techniques may be robust enough for clinical tests.
Network marker synthesis (NMS): seeking meaningful network markers from the MRT-test
It is natural to extend the biomarkers obtained from the MRT-test to corresponding network markers to enhance its reproducibility by capturing more meaningful gene markers, because some statistically expressed genes in array data may not be the "real" gene markers in clinical tests and vice versa. We propose a network marker synthesis (NMS), a bottom-up network marker construction algorithm, by growing from the MRT-test identified seed gene markers into network-based biomarkers through protein-protein networks (PPI). Compared with the existing top-down subnetwork marker construction methods (e.g., jActiveModule, PNA) 34 , our NMS method has a more targeted search and less dependence on the global network because it starts from meaningful gene markers identified by the MRT-test. Moreover, NMS outputs a small scale network consisting of several subnetwork markers connected by bridge genes instead of orthogonal subnetworks. Thus, it can identify the gene regulators for subnetwork markers, which can be a key issue to understand the network dynamics related to a complex disease. The basic idea of our NMS can be sketched as following steps.
(1) Starting from few gene markers from our MRT-test to induce corresponding subnetworks with differentially expressed genes by checking a global PPI network, which is the human PPI network from BioGrid 3.1.77, which has 39,331 protein-protein interactions between 10,271 proteins (genes) 38 . (2) Identifying top bridge genes linking the subnetworks and top connection genes that are elements in each subnetwork with direct-interaction with the selected bridge genes by some thresholds. We define the five key concepts in our algorithm as follows before we present our network marker synthesis (NMS) method in algorithm 2.
(1). Global PPI networks and total gene lists. The global PPI network G ppi = (V ppi , E ppi ) is a graph where V ppi denotes a set of proteins/genes (nodes) and E ppi represent a set of edges (interactions) between the proteins in V ppi . G ppi in our context refers to the human PPI network from BioGrid 3.1.77
38 . The total gene list T (T ⊆ V ppi ) includes all genes in the input expression profile X.
(2). Gene cliques and semi-gene cliques. A gene clique C is a fully connected subnetwork C = (V, E), where all the gene g i ∈ V, g j ∈ V, (g i , g j ) ∈ E, i.e., each node in a gene clique C has a maximal degree |V | − 1. A semi-gene clique is a subnetwork where each gene has a degree at least |V | − 2. Clearly, a gene clique is always a semi-gene clique but not vice versa. It is noted that we require the smallest clique at least has three nodes, i.e., |V | ≥ 3, in our algorithm.
(3). Bridging genes. A bridging/bridge gene b ∈ T is a gene which connects two or more subnetworks by interacting with at least one gene in each subnetwork. For example, the bridging gene b connecting two subnetworks S 1 = (V 1 , E 1 ) and
It is noted a bridging gene can be a gene that does not belong to any subnetworks according to our definition. A bridging gene usually has a large degrees (e.g., 355), i.e., it interacts with quite a lot genes in the whole network. As such, the few top bridging genes are actually regulators of the network marker inferred by our NMS method.
(4). Connection genes. Given a bridging gene b and a subnetwork S 1 = (V 1 , E 1 ), a connection gene c is the gene in S 1 (or V 1 ) that interacts with a bridging gene b directly, i.e., (b, c) ∈ E 1 . As an interface in each subnetwork that interacts with the bridging gene, a connection gene plays an essential role along the bridging genes to create other subnetworks that interact with the subnetwork markers induced by the original gene markers. Note that the top bridging genes are the regulators of the identified subnetwork markers, while the connection genes act as a local interface to process signals from a regulator. A bridge hub collects almost all qualified genes in the total gene list T interacting with the regulator and related connection genes, and works as an inferred subnetwork marker.
To grow gene markers into subnetwork markers, we use the MRT-test identified gene markers G M = {g 1 , g 2 , . . . g k } to induce their corresponding subnetworks S 1 , S 2 , . . . , S k by collecting all the genes in T interacting with the gene markers in G M by querying the global network G ppi , i.e.,
Genes with p-values (from MRT-test) less than a cutoff α (e.g., 0.001) are kept for each subnetwork.
The subnetworks are further sorted by their cardinalities-the 'orphan' subnetworks with only one entry are removed. Next, the bridging genes for the top K subnetworks with the largest cardinalities (K ≤ k) are identified and further sorted according to their PPI numbers. We choose a set of top bridging genes b 1 , b 2 , . . . , b M with the largest PPI numbers as 'real ' bridging genes, and identify their corresponding connection genes c
with respect to each subnetwork S i ,i = 1, 2, . . . K. We also compute the bridge hub H b for each bridge gene b i collecting all semi-gene cliques via searching G ppi . Finally, we collect all subnetwork markers by taking the set-union for all bridge hubs and the K subnetworks. Algorithm 2 below provides the detailed procedure for our NMS algorithm. greedily collect the semi-gene cliques with the richest interactions for each bridging gene.
3.4.1. Network markers inference for Stroma data. Figure 8 shows the network markers inferred from our NMS algorithm, where TP53, HDAC1, and BRCA1 (within rectangles) are the bridging genes identified, all of which are famous tumor genes related to general cancer (e.g., TP53) or widely known breast cancer marker (e.g., BRCA1) 39, 40 . As highly connected genes interacting with other genes, these bridging genes have 322, 297, and 172 unique interactions in the global PPI network respectively.
The bridging genes act as network regulators that enable and facilitate communication between different subnetworks. It is interesting to note that induced subnetworks (from our three seed gene markers) are orthogonal, and they and the other genes located in subnetworks (induced by semi-gene cliques) communicate with each other via the bridging genes.
In fact, all the three bridge genes are well-known breast cancer associated genes or oncogenes: HDAC1 has been reported as an important indicator in malignant human breast prognosis in previous RT-PCR analysis 39 , BRCA1 is a key gene associated with breast cancer and its mutation usually increases breast cancer risk, and TP53 is a well-known oncogene that mutates in most types of human cancers 2,39,40 . Furthermore, UBE2I & RB1, UBE2I & CDK9, and BRMS1 & RB1 are identified as the connection genes between the bridging genes BRCA1, TP53, and HDAC1, and the two subnetworks induced by GOLGB1 and CCNT2 respectively (e.g., UBE2I and RB1 are two different connection genes for BRCA1 with respect to the two induced subnetworks). CTNNB1 is identified as the connection gene between HDAC1 and the subnetwork induced by CBY1.
There are seven bridge hubs generated by collecting the semi-gene cliques for the bridging and connection genes. For example, the bridge hub induced by BRCA1 and the connection gene UBE2I has five other genes: AR, TP53, JUN, PIAS1, and SUMO1. Some genes in these bridge hubs demonstrate high relevance with respect to breast cancer. For instance, Smith et al have reported that JUN over-expressed in some breast cancer cells may result in the production of tumorigenic, invasive, and hormone-resistant phenotypes 39 . Park et al also reported that SUMO1 negatively regulated BRCA1-mediated transcription 40, 41 . Gonzalez et al reported that ARpositive tumors had a significant longer overall survival than those with AR-negative breast carcinomas in their tumor analysis of androgen receptors (AR) 42, 43 . Finally, we employed the network markers consisting of 32 genes to conduct classification under a 5-fold CV using a SVM classifier with a linear kernel and achieved diagnostic accuracy 97.78% with 100% sensitivity and 90% specificity. It is noted that the best diagnostic result among other classifiers' performance under the same cross validation condition is achieved by the PLS-LLD algorithm with diagnostic accuracy 93.78% by using the whole data sets, which still fall behind our network marker methods' result. The superiority demonstrated by our network markers is due to the good gene markers identified by the MRT-test and more targeted search based on the gene markers in the network marker synthesis (NMS).
Similarly, we identified the network markers for the CNS data 15 by using the top 10 gene markers from the MRT-test. Among them, four gene markers APC, DCTN1, APBA2, and JMJD1C led to non-trivial subnetworks with 46, 9, 6, and 3 genes respectively, after collecting interactions among the total 5569 genes in the input data using the p-value cutoff α=0.001. Again, APC and APBA2 mutations have been reported to play an important role in medulloblastoma 26 ; DCTN1 and JMJD1C were reported associated with neuron diseases and glioma respectively 28 . The details of the bridging gene information of this network marker can be found in the supplemental materials.
Discussion
In this work, we have presented a novel feature selection and biomarker discovery algorithm MRT-test and investigate its application in effective phenotype diagnosis. The MRT-test is designed to be able to detect subtle data behaviors so that phenotype samples with similar global features but different local features can be effectively detected, which is essential for the rival-clinical diagnosis in translational bioinformatics. We demonstrated that our MRT-test can separate different phenotypes from high-dimensional omics profiles, including those challenging gene expression datasets that were previously thought to be non-separable based on other existing methods. Our proposed MRT-test not only provides an effective biomarker discovery approach, but also demonstrated that high-dimensional gene/protein expression data's linear separability, which provides a strong support for employing effective biomarker patterns in complex disease diagnosis in translational bioinformatics.
Although our MRT-test can achieve almost perfect phenotype separation by using only three top selected gene markers for almost all data in our experiment, the three top-ranked gene markers from the MRT-test for the Prostate data, an old gene expression array data published in 2002 12 , can not achieve a perfect phenotype separation as the other data when we only use the first-PC in MRT-test to conduct the detail coefficient matrix reconstruction, which seems to be consistent to its late arrival performance in classification. However, such case may suggest us that more PCs should be used in the detail coefficient matrix reconstruction process for the MRT-test for some omics data.
By integrating our MRT-test with the state-of-the-art classifiers, we showed that we can achieve consistent clinical-level diagnosis accuracy across a series of omics data in disease phenotype discrimination by comparing our methods with the state-of-the-arts. It is noted that the rivaling-clinical diagnosis performance is due to the novelty of our techniques proposed in our unique MRT-test. Our results are obtained from different omics data under rigorous cross validation, which prevents any possibility of overfitting because overfitting may only produce deceptive diagnostic performance for one or two data but it has no way to generalize the similar performance to the other data, not to mention a series of heterogeneous gene/protein expression array data.
We also proposed a bottom-up network marker identification (NMS) algorithm by starting from the MRT-test identified biomarkers to identify corresponding network markers. Unlike the existing top-down subnetwork marker identification algorithms, our NMS algorithm has less dependence on the global network due to its more targeted search, and enables to identify regulatory genes for its special network marker building technique, which can lead to useful insights about the complex diseases. Alternatively, we have to point out that our NMS is an algorithm that relies on the MRT-test, which is theoretically not as rigorous or independent as the existing subnetwork marker identification algorithms such as jActiveModule, COSINE, and PNA 3,4,5 . Although our methods achieved exceptional diagnostic performance and biomarker discovery for benchmark omics data, we are collaborating pathologists to apply our algorithms to different individual data sets because the current results are from secondary data analysis for public data, in addition to further extending our NMS method to proteomics data. Although it is still not theoretically clear how multi-resolution corresponds to underling biological or phenotype behaviors, our work suggests the multi-resolution analysis approach is an effective way to separate the true signals from red herrings, which obviously contributes to high performance diagnosis in translational bioinformatics. As for future work, we are interested in integrating gene expression, protein expression, microRNA expression, and RNASeq data 44 by using TCGA data 45 to infer consensus network markers by extending our MRT-test and network marker synthesis algorithms, in addition to investigating how the ordering of samples in an omics data set will our MRT-test results. He has a long-standing interest in cross-disciplinary computer science research and has published more than 100 papers in leading peer-reviewed journals and conferences. His primary research is in machine learning and data mining, with applications in text mining, bioinformatics, privacy-preserving data mining, and social network mining.
